US 11253591
Combination of lenalidomide and polypeptide construct, and uses thereof
granted A61KA61K2039/505A61K31/454
Quick answer
US patent 11253591 (Combination of lenalidomide and polypeptide construct, and uses thereof) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K31/454, A61K38/212, A61K39/39558